podophyllotoxin: clinical use

Prescribing considerations

• Confirm that lesions are external genital warts at a licensed anatomical site.
• Treatment areas larger than 4 cm² should be managed under direct healthcare-professional supervision.
• Avoid mucosa, healthy surrounding tissue and occlusive dressings.
• Advise avoiding sexual contact during treatment and until skin has healed; if sex occurs, a condom should be used.
• Safety and efficacy have not been established in people under 18 years.

Contraindications and cautions

• Hypersensitivity to podophyllotoxin or a formulation excipient
• Application to open or bleeding wounds
• Concurrent use of another podophyllotoxin-containing preparation

Monitoring

• Assess local response, skin integrity and treatment tolerability.
• Stop treatment and review promptly if severe local pain, burning, bleeding, swelling or itching develops.
• Routine systemic monitoring is not specified; systemic absorption after appropriate topical use is expected to be low.

Clinical pharmacology

Podophyllotoxin inhibits metaphase by binding tubulin and preventing microtubule assembly. Its local cytotoxic action inhibits growth of virus-infected wart cells; systemic absorption from recommended topical use is expected to be low.

Formulation and product differences

• The cream is applied with a fingertip and contains excipients that may cause contact dermatitis or delayed allergic reactions.
• The solution is applied with supplied disposable applicators, must dry before skin surfaces meet, and is ethanol-containing and flammable.
• Both formulations share the same licensed anatomical indication and principal contraindications.